AIM ImmunoTech Inc. (NYSE:AIM - Get Free Report)'s stock price gapped up before the market opened on Friday . The stock had previously closed at $8.30, but opened at $9.13. AIM ImmunoTech shares last traded at $8.99, with a volume of 68,101 shares trading hands.
AIM ImmunoTech Stock Up 3.1%
The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $7.26 million, a PE ratio of -20.21 and a beta of 0.94. The stock's fifty day simple moving average is $9.13 and its 200-day simple moving average is $14.10.
About AIM ImmunoTech
(
Get Free Report)
AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).
Recommended Stories
Before you consider AIM ImmunoTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AIM ImmunoTech wasn't on the list.
While AIM ImmunoTech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
